• Strengthened financial position with $5.2m underwriting of RHYO options
• Continued commercial rollout of ColoSTAT® with expanded collection network
• Enhanced clinician engagement and national GP awareness campaign
• Strategic partnerships expanded at BIO International Convention 2026
• Independent evaluation of ColoSTAT® in progress

Rhythm Biosciences Ltd, a commercial-stage precision diagnostics company, released its Quarterly Activities Report for Q4 FY26. The report highlights key achievements, including a strengthened financial position through the underwriting of $5.2 million of RHYO options, supporting commercial activities. The company continued its commercial rollout of ColoSTAT®, a blood-based colorectal cancer detection test, with an expanded collection network through 4Cyte Pathology. Clinician engagement was enhanced with targeted education, participation in primary care conferences, and a national GP awareness campaign. Strategic partnerships were expanded at BIO International Convention 2026, generating multiple strategic partnering opportunities. The independent analytical evaluation of ColoSTAT® at the Southern Hub Laboratory continued, supporting future commercial, reimbursement, and market access opportunities.

Expect cash reserves to fund operations through 4Q FY27

Rhythm Biosciences aims to expand market access, clinician engagement, and commercial infrastructure to support sustained growth in diagnostic utilization.